Mandate

Vinge advised Ysios Capital, OrbiMed and others in connection with their investment in Galecto Biotech

Galecto Biotech AB, the developer of galectin modulators for the treatment of severe diseases, including fibrosis and cancer, has closed a €79 million financing co-led by Ysios Capital and OrbiMed.

New investors Ysios Capital, OrbiMed, HBM Healthcare Investments, OrbiMed Israel, Bristol Myers-Squibb, Maverick Ventures and Seventure Partners joined existing investors Novo Seeds, M Ventures, and Sunstone Capital in the financing round.
 
Vinge advised the new investors. The Vinge team included Jesper Ottergren, Erik Sjöman and Charlotte Akej.
 

Related

Vinge advises Spotlight Group in connection with offer from Kriptown

Vinge is advising Spotlight Group AB (publ) in connection with Kriptown SAS having made a public cash takeover offer to the shareholders of Spotlight Group.
June 17, 2026

Vinge has advised EQT IX in connection with its exit of Beijer Ref AB (publ)

Vinge has advised EQT IX (”EQT”) in connection with the sale of all of its remaining shares of series B in Beijer Ref AB (publ) through an accelerated bookbuilding process carried out on 15 June 2026.
June 16, 2026

Vinge has advised Accent Equity VI and the minority shareholders on their divestment of Malte Månson

Vinge has advised Accent Equity VI and the minority shareholders on their divestment of Malte Månson to Citira, a European tire management provider and portfolio company of Norvestor. Headquartered in Stockholm, Malte Månson is an independent service and repair provider for commercial vehicles and operates a network of 28 service workshop locations across Sweden, authorized by brands such as MAN, DAF, IVECO, Mercedes-Benz, Setra, VDL and EVO. Malte Månson has an annual revenue of SEK 800 million and employs over 300 full-time professionals.
June 08, 2026